 | Form 4 Filings | Insider Buys | Significant Buys | Penny Stocks Insider Buying | Insider Sales |
| Insider Buy Sell Ratios | Stock Options | Insider Trading Stock Screener | Insider Trading Graph View | Insider Watch |
Insider Trading - NovoCure Ltd (NVCR)
| | "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise" - Peter Lynch What is insider trading>> |
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2020-02-24 Sale | 2020-02-26 5:10 pm | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 11,647 | $81.16 | $945,224 | 205,226 (Direct) | View |
| 2020-02-24 Sale | 2020-02-26 5:14 pm | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 8,482 | $81.16 | $688,365 | 67,119 (Direct) | View |
| 2020-02-24 Sale | 2020-02-26 5:17 pm | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 18,908 | $81.16 | $1,534,498 | 111,768 (Direct) | View |
| 2020-02-25 Sale | 2020-02-28 4:41 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 12,999 | $80.08 | $1,040,943 | 67,721 (Direct) | View |
| 2020-02-27 Sale | 2020-03-02 5:11 pm | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 2,643 | $72.21 | $190,864 | 70,032 (Direct) | View |
| 2020-02-27 Sale | 2020-03-02 5:13 pm | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 3,893 | $72.21 | $281,133 | 514,831 (Direct) | View |
| 2020-02-27 Sale | 2020-03-02 5:17 pm | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 2,673 | $72.21 | $193,031 | 208,726 (Direct) | View |
| 2020-02-27 Sale | 2020-03-02 5:22 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 1,601 | $72.21 | $115,616 | 69,206 (Direct) | View |
| 2020-03-02 Sale | 2020-03-05 4:47 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 1,485 | $72.97 | $108,360 | 67,721 (Direct) | View |
| 2020-04-13 Sale | 2020-04-15 5:03 pm | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 58,500 | $70.11 | $4,101,564 | 220,867 (Direct) | View |
| 2020-05-01 Sale | 2020-05-05 4:32 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 1,184 | $60.08 | $71,134 | 101,842 (Direct) | View |
| 2020-05-05 Sale | 2020-05-07 4:41 pm | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 60,164 | $63.36 | $3,812,170 | 567,883 (Direct) | View |
| 2020-05-05 Sale | 2020-05-07 4:48 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 1,149 | $62.2 | $71,468 | 100,693 (Direct) | View |
| 2020-05-07 Sale | 2020-05-11 4:17 pm | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 62,896 | $64.11 | $4,032,390 | 681,290 (Direct) | View |
| 2020-05-11 Sale | 2020-05-12 4:13 pm | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 31,332 | $63.73 | $1,996,726 | 649,958 (Direct) | View |
| 2020-05-08 Sale | 2020-05-12 4:22 pm | NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer | 1,611 | $63.73 | $102,666 | 15,211 (Direct) | View |
| 2020-05-12 Sale | 2020-05-14 4:14 pm | NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer | 2,595 | $64.78 | $168,104 | 12,616 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2020-02-24 Exercise | 2020-02-26 5:10 pm | N/A N/A | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 31,199 | $88.26 | 205,226 (Direct) | View |
| 2020-02-24 Exercise | 2020-02-26 5:10 pm | 2020-02-22 N/A | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 31,199 | $0 | 205,226 (Direct) | View |
| 2020-02-24 Exercise | 2020-02-26 5:14 pm | N/A N/A | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 21,666 | $88.26 | 67,119 (Direct) | View |
| 2020-02-24 Exercise | 2020-02-26 5:14 pm | 2020-02-22 N/A | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 21,666 | $0 | 67,119 (Direct) | View |
| 2020-02-24 Exercise | 2020-02-26 5:17 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 43,333 | $88.26 | 111,768 (Direct) | View |
| 2020-02-24 Exercise | 2020-02-26 5:17 pm | 2020-02-22 N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 43,333 | $0 | 111,768 (Direct) | View |
| 2020-02-24 Exercise | 2020-02-26 5:18 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 12,999 | $88.26 | 0 (Direct) | View |
| 2020-02-24 Exercise | 2020-02-26 5:18 pm | 2020-02-22 N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 12,999 | $0 | 0 (Direct) | View |
| 2020-02-24 Exercise | 2020-02-26 5:19 pm | N/A N/A | NovoCure Ltd | NVCR | Danziger Asaf CEO | 53,333 | $88.26 | 0 (Direct) | View |
| 2020-02-24 Exercise | 2020-02-26 5:19 pm | 2020-02-22 N/A | NovoCure Ltd | NVCR | Danziger Asaf CEO | 53,333 | $0 | 0 (Direct) | View |
| 2020-02-27 Exercise | 2020-03-02 5:11 pm | N/A N/A | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 5,556 | $79.45 | 70,032 (Direct) | View |
| 2020-02-27 Exercise | 2020-03-02 5:11 pm | 2019-02-27 N/A | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 5,556 | $0 | 70,032 (Direct) | View |
| 2020-02-27 Exercise | 2020-03-02 5:13 pm | N/A N/A | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 9,259 | $79.45 | 514,831 (Direct) | View |
| 2020-02-27 Exercise | 2020-03-02 5:13 pm | 2019-02-27 N/A | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 9,259 | $0 | 514,831 (Direct) | View |
| 2020-02-27 Exercise | 2020-03-02 5:15 pm | N/A N/A | NovoCure Ltd | NVCR | Danziger Asaf CEO | 9,259 | $79.45 | 9,259 (Direct) | View |
| 2020-02-27 Exercise | 2020-03-02 5:15 pm | 2020-02-27 N/A | NovoCure Ltd | NVCR | Danziger Asaf CEO | 9,259 | $0 | 9,259 (Direct) | View |
| 2020-02-27 Exercise | 2020-03-02 5:17 pm | N/A N/A | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 6,173 | $79.45 | 208,726 (Direct) | View |
| 2020-02-27 Exercise | 2020-03-02 5:17 pm | 2020-02-27 N/A | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 6,173 | $0 | 208,726 (Direct) | View |
| 2020-02-27 Exercise | 2020-03-02 5:18 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 7,716 | $0 | 7,716 (Direct) | View |
| 2020-02-27 Exercise | 2020-03-02 5:18 pm | 2020-02-27 N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 7,716 | $0 | 7,716 (Direct) | View |
| 2020-02-27 Exercise | 2020-03-02 5:22 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 3,086 | $79.45 | 69,206 (Direct) | View |
| 2020-02-27 Exercise | 2020-03-02 5:22 pm | 2019-02-27 N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 3,086 | $0 | 69,206 (Direct) | View |
| 2020-03-03 Option Award | 2020-03-05 6:46 pm | N/A N/A | NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer | 14,415 | $0 | 27,794 (Direct) | View |
| 2020-03-03 Option Award | 2020-03-05 6:46 pm | N/A 2030-03-02 | NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer | 27,794 | $69.37 | 27,794 (Direct) | View |
| 2020-03-03 Option Award | 2020-03-05 6:50 pm | N/A N/A | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 19,220 | $0 | 37,058 (Direct) | View |
| 2020-03-03 Option Award | 2020-03-05 6:50 pm | N/A 2030-03-02 | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 37,058 | $69.37 | 37,058 (Direct) | View |
| 2020-03-03 Option Award | 2020-03-05 6:55 pm | N/A N/A | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 14,415 | $0 | 27,794 (Direct) | View |
| 2020-03-03 Option Award | 2020-03-05 6:55 pm | N/A 2030-03-02 | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 27,794 | $69.37 | 27,794 (Direct) | View |
| 2020-03-03 Option Award | 2020-03-05 6:57 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 24,025 | $0 | 46,323 (Direct) | View |
| 2020-03-03 Option Award | 2020-03-05 6:57 pm | N/A 2030-03-02 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 46,323 | $69.37 | 46,323 (Direct) | View |
| 2020-03-03 Option Award | 2020-03-05 6:58 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 21,623 | $0 | 41,690 (Direct) | View |
| 2020-03-03 Option Award | 2020-03-05 6:58 pm | N/A 2030-03-02 | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 41,690 | $69.37 | 41,690 (Direct) | View |
| 2020-03-04 Gift | 2020-03-06 4:22 pm | N/A 2028-02-26 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 84,483 | $21.15 | 1,644 (Direct) | View |
| 2020-03-04 Gift | 2020-03-06 4:22 pm | N/A 2028-02-26 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 84,483 | $21.15 | 1,644 (Indirect) | View |
| 2020-03-04 Gift | 2020-03-06 4:22 pm | N/A 2027-02-21 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 219,373 | $7.15 | 1,644 (Direct) | View |
| 2020-03-04 Gift | 2020-03-06 4:22 pm | N/A 2027-02-21 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 219,373 | $7.15 | 1,644 (Indirect) | View |
| 2020-03-04 Gift | 2020-03-06 4:22 pm | N/A 2026-01-12 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 300,030 | $21.9 | 1,644 (Direct) | View |
| 2020-03-04 Gift | 2020-03-06 4:22 pm | N/A 2026-01-12 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 298,386 | $21.9 | 1,644 (Indirect) | View |
| 2020-03-04 Gift | 2020-03-06 4:22 pm | N/A 2026-01-12 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 1,644 | $21.9 | 1,644 (Indirect) | View |
| 2020-03-06 Sale | 2020-03-10 4:13 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 3,123 | $69.53 | 140,386 (Direct) | View |
| 2020-03-06 Sale | 2020-03-10 4:15 pm | N/A N/A | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 2,499 | $69.53 | 86,753 (Direct) | View |
| 2020-03-06 Sale | 2020-03-10 4:18 pm | N/A N/A | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 4,320 | $69.53 | 510,511 (Direct) | View |
| 2020-03-06 Sale | 2020-03-10 4:20 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 2,906 | $69.53 | 14,518 (Direct) | View |
| 2020-03-06 Exercise | 2020-03-10 4:20 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 17,500 | $7.48 | 14,518 (Direct) | View |
| 2020-03-06 Sale | 2020-03-10 4:20 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 3,245 | $64.27 | 14,518 (Direct) | View |
| 2020-03-06 Exercise | 2020-03-10 4:20 pm | N/A 2024-02-25 | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 17,500 | $7.48 | 14,518 (Direct) | View |
| 2020-03-06 Sale | 2020-03-10 4:22 pm | N/A N/A | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 2,274 | $69.53 | 220,867 (Direct) | View |
| 2020-04-13 Exercise | 2020-04-15 5:03 pm | N/A N/A | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 22,755 | $7.15 | 220,867 (Direct) | View |
| 2020-04-13 Exercise | 2020-04-15 5:03 pm | N/A N/A | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 35,745 | $7.15 | 220,867 (Direct) | View |
| 2020-04-13 Exercise | 2020-04-15 5:03 pm | N/A 2027-02-21 | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 22,755 | $7.15 | 220,867 (Direct) | View |
| 2020-04-13 Exercise | 2020-04-15 5:03 pm | N/A 2027-02-21 | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 35,745 | $7.15 | 220,867 (Direct) | View |
| 2020-05-01 Exercise | 2020-05-05 4:32 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 2,333 | $65.8 | 101,842 (Direct) | View |
| 2020-05-01 Exercise | 2020-05-05 4:32 pm | 2019-05-01 N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 2,333 | $0 | 101,842 (Direct) | View |
| 2020-05-04 Exercise | 2020-05-06 5:52 pm | N/A N/A | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 58,768 | $60.48 | 235,071 (Direct) | View |
| 2020-05-04 Exercise | 2020-05-06 5:52 pm | 2020-05-04 N/A | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 58,768 | $0 | 235,071 (Direct) | View |
| 2020-05-05 Exercise | 2020-05-07 4:41 pm | N/A N/A | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 58,768 | $61.4 | 567,883 (Direct) | View |
| 2020-05-05 Exercise | 2020-05-07 4:41 pm | N/A N/A | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 58,768 | $64.15 | 567,883 (Direct) | View |
| 2020-05-05 Exercise | 2020-05-07 4:41 pm | 2020-05-06 N/A | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 58,768 | $0 | 567,883 (Direct) | View |
| 2020-05-05 Exercise | 2020-05-07 4:41 pm | 2020-05-06 N/A | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 58,768 | $0 | 567,883 (Direct) | View |
| 2020-05-07 Exercise | 2020-05-11 4:17 pm | N/A N/A | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 58,768 | $64.77 | 681,290 (Direct) | View |
| 2020-05-07 Exercise | 2020-05-11 4:17 pm | N/A N/A | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 58,767 | $63.84 | 681,290 (Direct) | View |
| 2020-05-07 Exercise | 2020-05-11 4:17 pm | 2020-05-07 N/A | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 58,768 | $0 | 681,290 (Direct) | View |
| 2020-05-07 Exercise | 2020-05-11 4:17 pm | 2020-05-08 N/A | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 58,767 | $0 | 681,290 (Direct) | View |
| 2020-05-08 Exercise | 2020-05-11 4:22 pm | N/A N/A | NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer | 1,402 | $63.84 | 2,803 (Direct) | View |
| 2020-05-08 Exercise | 2020-05-11 4:22 pm | 2020-05-08 N/A | NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer | 1,402 | $0 | 2,803 (Direct) | View |
| 2020-05-08 Exercise | 2020-05-12 4:22 pm | N/A N/A | NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer | 4,206 | $63.84 | 15,211 (Direct) | View |
| 2020-05-08 Exercise | 2020-05-12 4:22 pm | 2020-05-08 N/A | NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer | 4,206 | $0 | 15,211 (Direct) | View |
| 2020-06-10 Option Award | 2020-06-12 6:03 pm | N/A N/A | NovoCure Ltd | NVCR | McCoy Sherilyn S Director | 2,541 | $0 | 5,101 (Direct) | View |
| 2020-06-10 Option Award | 2020-06-12 6:03 pm | N/A 2030-06-10 | NovoCure Ltd | NVCR | McCoy Sherilyn S Director | 5,101 | $67.89 | 5,101 (Direct) | View |
| 2020-06-10 Option Award | 2020-06-12 6:07 pm | N/A N/A | NovoCure Ltd | NVCR | Hung David Director | 2,541 | $0 | 5,101 (Direct) | View |
| 2020-06-10 Option Award | 2020-06-12 6:07 pm | N/A 2030-06-10 | NovoCure Ltd | NVCR | Hung David Director | 5,101 | $67.89 | 5,101 (Direct) | View |
| 2020-06-10 Option Award | 2020-06-12 6:09 pm | N/A N/A | NovoCure Ltd | NVCR | Madden Martin J. Director | 2,541 | $0 | 5,101 (Direct) | View |
| 2020-06-10 Option Award | 2020-06-12 6:09 pm | N/A 2030-06-10 | NovoCure Ltd | NVCR | Madden Martin J. Director | 5,101 | $67.89 | 5,101 (Direct) | View |
| 2020-06-10 Option Award | 2020-06-12 6:11 pm | N/A N/A | NovoCure Ltd | NVCR | VERNON W ANTHONY Director | 2,541 | $0 | 5,101 (Direct) | View |
| 2020-06-10 Option Award | 2020-06-12 6:11 pm | N/A 2030-06-10 | NovoCure Ltd | NVCR | VERNON W ANTHONY Director | 5,101 | $67.89 | 5,101 (Direct) | View |
| 2020-06-10 Option Award | 2020-06-12 6:12 pm | N/A N/A | NovoCure Ltd | NVCR | HILLEMAN JERYL L Director | 2,541 | $0 | 5,101 (Direct) | View |
| 2020-06-10 Option Award | 2020-06-12 6:12 pm | N/A 2030-06-10 | NovoCure Ltd | NVCR | HILLEMAN JERYL L Director | 5,101 | $67.89 | 5,101 (Direct) | View |
| 2020-06-10 Option Award | 2020-06-12 6:14 pm | N/A N/A | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 2,541 | $0 | 5,101 (Direct) | View |
| 2020-06-10 Option Award | 2020-06-12 6:14 pm | N/A 2030-06-10 | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,101 | $67.89 | 5,101 (Direct) | View |